Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer
Stephanie L. Tzetzo(Roswell Park Comprehensive Cancer Center), Agnieszka K. Witkiewicz(Southwestern Medical Center)
Cited by 4
Related Papers
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
|Nature Communications|2015|1.1k
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
|Cancer Research|2024|45
RB loss sensitizes triple-negative breast cancer to apoptosis induced by cellular stress
|Cell Death Discovery|2025|2
Targeting dual signaling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2019|1